New antibody takes aim at stubborn lupus in early trial
NCT ID NCT06400537
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug called A-319 in 25 adults with active or treatment-resistant systemic lupus erythematosus (SLE). The drug is designed to target and help control overactive immune cells. The main goal is to see if it is safe and tolerable, while also checking how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanxi Bethune Hospital
RECRUITINGTaiyuan, Shanxi, 030032, China
Contact Email: •••••@•••••
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.